Please login to the form below

Not currently logged in
Email:
Password:

IOmet

This page shows the latest IOmet news and features for those working in and with pharma, biotech and healthcare.

Merck & Co buys another immuno-oncology target

Merck & Co buys another immuno-oncology target

Other deals have included the acquisitions of IOmet last year, cCAM Biotherapeutics in 2015 and OncoEthix a year earlier.

Latest news

  • Merck & Co buys IOmet to boost immuno-oncology tech Merck & Co buys IOmet to boost immuno-oncology tech

    IOmet will become a wholly owned subsidiary of Merck after the transaction goes through, according to Merck. ... IOmet's chief executive Alan Wise said becoming part of Merck "creates significant opportunity for us to advance the treatment of cancer.".

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics